|
| 澳华内镜(688212)限售解禁 | | 解禁日期 | 本期流通股本
(万股) | 本期流通股本占
总股本比例(%) | 已流通股本
(万股) | 未流通股本
(万股) | 流通A股
(万股) | 流通A股占
总股本比例(%) | 限售股类型 | | 2024-11-15 | 4182.28 | 31.22% | 13395.50 | 0.00 | 9151.10 | 68.31% | 首发原股东限售股份 | | 2024-01-18 | 7.80 | 0.06% | 9221.02 | 4182.28 | 9221.02 | 68.80% | 股权激励一般股份 | | 2023-11-15 | 166.70 | 1.24% | 9213.22 | 4182.28 | 9151.10 | 68.31% | 首发战略配售股份 | | 2023-06-09 | 61.50 | 0.46% | 9210.22 | 4185.28 | 9210.22 | 68.76% | 股权激励一般股份 | | 2022-11-15 | 6113.13 | 45.85% | 8985.02 | 4348.98 | 8985.02 | 67.38% | 首发战略配售股份,首发原股东限售股份 | | 2022-05-16 | 121.11 | 0.91% | 3033.21 | 10300.79 | 3033.21 | 22.75% | 首发机构配售股份 |
|